$ALDX
Aldeyra Therapeutics, Inc.

2022 Q4 Form 10-Q Financial Statement

#000095017022024434 Filed on November 10, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.735M $3.245M $2.547M
YoY Change 84.77% 27.41% 12.69%
% of Gross Profit
Research & Development $8.961M $11.54M $12.89M
YoY Change -30.21% -10.51% 110.23%
% of Gross Profit
Depreciation & Amortization $66.65K $65.31K $68.35K
YoY Change 8.78% -4.45% -14.56%
% of Gross Profit
Operating Expenses $13.70M $11.54M $12.89M
YoY Change -11.08% -10.51% 110.23%
Operating Profit -$14.78M -$15.44M
YoY Change -4.25% 84.06%
Interest Expense $794.6K $416.9K $413.1K
YoY Change -326.84% 0.92% -15.55%
% of Operating Profit
Other Income/Expense, Net $231.3K -$353.8K
YoY Change -165.38% -26.9%
Pretax Income -$12.90M -$14.55M -$15.79M
YoY Change -18.11% -7.86% 78.01%
Income Tax
% Of Pretax Income
Net Earnings -$12.90M -$14.55M -$15.79M
YoY Change -18.11% -7.86% 78.01%
Net Earnings / Revenue
Basic Earnings Per Share -$0.25 -$0.27
Diluted Earnings Per Share -$0.22 -$0.25 -$272.2K
COMMON SHARES
Basic Shares Outstanding 58.56M 58.32M 57.86M
Diluted Shares Outstanding 58.46M 58.02M

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $174.3M $185.3M $241.4M
YoY Change -24.15% -23.22% 180.01%
Cash & Equivalents $144.4M $128.7M $241.4M
Short-Term Investments $29.88M $56.68M $0.00
Other Short-Term Assets $3.242M $4.154M $5.403M
YoY Change 9.46% -23.13% 170.16%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $181.0M $189.5M $246.8M
YoY Change -22.23% -23.22% 179.81%
LONG-TERM ASSETS
Property, Plant & Equipment $19.28K $26.66K $39.61K
YoY Change -40.66% -32.69% -50.15%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $268.5K $208.6K $445.6K
YoY Change -30.13% -53.19% 238.49%
TOTAL ASSETS
Total Short-Term Assets $181.0M $189.5M $246.8M
Total Long-Term Assets $268.5K $208.6K $445.6K
Total Assets $181.3M $189.7M $247.2M
YoY Change -22.24% -23.27% 179.9%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $133.6K $1.307M $467.9K
YoY Change -86.9% 179.3% 277.67%
Accrued Expenses $14.07M $10.25M $11.25M
YoY Change 33.66% -8.87% 180.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $911.8K $12.45M $0.00
YoY Change -100.0%
Total Short-Term Liabilities $15.36M $24.20M $11.94M
YoY Change 30.48% 102.6% 83.73%
LONG-TERM LIABILITIES
Long-Term Debt $14.92M $3.303M $15.42M
YoY Change -3.74% -78.58% 21.49%
Other Long-Term Liabilities $0.00 $0.00 $184.6K
YoY Change -100.0% -100.0%
Total Long-Term Liabilities $14.92M $3.303M $15.42M
YoY Change -3.74% -78.58% 21.49%
TOTAL LIABILITIES
Total Short-Term Liabilities $15.36M $24.20M $11.94M
Total Long-Term Liabilities $14.92M $3.303M $15.42M
Total Liabilities $30.28M $27.50M $27.55M
YoY Change 10.52% -0.18% 43.48%
SHAREHOLDERS EQUITY
Retained Earnings -$356.7M -$343.8M -$278.9M
YoY Change 21.05% 23.26% 23.63%
Common Stock $507.8M $506.3M $498.6M
YoY Change 1.48% 1.54%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $151.0M $162.2M $219.7M
YoY Change
Total Liabilities & Shareholders Equity $181.3M $189.7M $247.2M
YoY Change -22.24% -23.27% 179.9%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$12.90M -$14.55M -$15.79M
YoY Change -18.11% -7.86% 78.01%
Depreciation, Depletion And Amortization $66.65K $65.31K $68.35K
YoY Change 8.78% -4.45% -14.56%
Cash From Operating Activities -$11.23M -$12.57M -$8.434M
YoY Change -2.99% 49.09% 35.16%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $27.00M $19.02M $0.00
YoY Change -100.0%
Cash From Investing Activities $27.00M $19.02M $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 1.197M 63.78K
YoY Change 1776.4% -99.76%
NET CHANGE
Cash From Operating Activities -11.23M -12.57M -8.434M
Cash From Investing Activities 27.00M 19.02M 0.000
Cash From Financing Activities 0.000 1.197M 63.78K
Net Change In Cash 15.77M 7.639M -8.370M
YoY Change -236.2% -191.26% -132.85%
FREE CASH FLOW
Cash From Operating Activities -$11.23M -$12.57M -$8.434M
Capital Expenditures $0.00 $0.00 $0.00
Free Cash Flow -$11.23M -$12.57M -$8.434M
YoY Change -2.99% 49.09% 35.16%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001341235
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36332
dei Entity Registrant Name
EntityRegistrantName
ALDEYRA THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-1968197
dei Entity Address Address Line1
EntityAddressAddressLine1
131 Hartwell Avenue
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 320
dei Entity Address City Or Town
EntityAddressCityOrTown
Lexington
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02421
dei City Area Code
CityAreaCode
781
dei Local Phone Number
LocalPhoneNumber
761-4904
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
dei Trading Symbol
TradingSymbol
ALDX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
58560078
CY2022Q3 aldx Cash And Money Market Funds
CashAndMoneyMarketFunds
107150541
CY2021Q4 aldx Cash And Money Market Funds
CashAndMoneyMarketFunds
104790989
CY2022Q3 aldx Cash Equivalent Reverse Repurchase Agreement
CashEquivalentReverseRepurchaseAgreement
21500000
CY2021Q4 aldx Cash Equivalent Reverse Repurchase Agreement
CashEquivalentReverseRepurchaseAgreement
125000000
CY2022Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
56678860
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
0
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4153721
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2961781
CY2022Q3 us-gaap Assets Current
AssetsCurrent
189483122
CY2021Q4 us-gaap Assets Current
AssetsCurrent
232752770
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
181943
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
351863
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
26660
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
32487
CY2022Q3 us-gaap Assets
Assets
189691725
CY2021Q4 us-gaap Assets
Assets
233137120
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1306926
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1019702
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10254451
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10523353
CY2022Q3 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
12449058
CY2021Q4 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
0
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
184599
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
229607
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
24195034
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
11772662
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
125232
CY2022Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
3303042
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
15503703
CY2022Q3 us-gaap Liabilities
Liabilities
27498076
CY2021Q4 us-gaap Liabilities
Liabilities
27401597
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
58560078
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
58560078
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
58081215
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
58081215
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
58560
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
58081
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
506235298
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
500369444
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-285733
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-343814476
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-294692002
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
162193649
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
205735523
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
189691725
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
233137120
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11539620
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12894344
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
38344594
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
32095132
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3244936
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2546807
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10638602
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8720161
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-14784556
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-15441151
us-gaap Operating Income Loss
OperatingIncomeLoss
-48983196
us-gaap Operating Income Loss
OperatingIncomeLoss
-40815293
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
648242
CY2021Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
59306
us-gaap Investment Income Interest
InvestmentIncomeInterest
1094001
us-gaap Investment Income Interest
InvestmentIncomeInterest
122732
CY2022Q3 us-gaap Interest Expense
InterestExpense
416917
CY2021Q3 us-gaap Interest Expense
InterestExpense
413110
us-gaap Interest Expense
InterestExpense
1233279
us-gaap Interest Expense
InterestExpense
1329166
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
231325
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-353804
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-139278
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1206434
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-14553231
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-15794955
us-gaap Net Income Loss
NetIncomeLoss
-49122474
us-gaap Net Income Loss
NetIncomeLoss
-42021727
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.25
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.25
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.27
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.27
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.84
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.84
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.80
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.80
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
58457863
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58457863
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
58019099
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58019099
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
58352991
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58352991
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52688846
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
52688846
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-14553231
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-15794955
us-gaap Net Income Loss
NetIncomeLoss
-49122474
us-gaap Net Income Loss
NetIncomeLoss
-42021727
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
30
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-285733
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
30
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
0
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-285733
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
0
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14553201
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-15794955
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-49408207
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-42021727
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
205735523
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4646241
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1123427
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
96665
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-285733
aldx Net Loss
NetLoss
-49122474
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
162193649
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
59508558
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5186689
aldx Issuance Of Common Stock Value In Connection With Acquisition Milestone
IssuanceOfCommonStockValueInConnectionWithAcquisitionMilestone
2499991
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
189811611
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4623251
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
61529
aldx Net Loss
NetLoss
-42021727
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
219669902
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
174029008
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1521074
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1123427
CY2022Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
73341
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
30
CY2022Q3 aldx Net Loss
NetLoss
-14553231
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
162193649
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
233679945
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1721134
CY2021Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
12124
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
51654
CY2021Q3 aldx Net Loss
NetLoss
-15794955
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
219669902
us-gaap Profit Loss
ProfitLoss
-49122474
us-gaap Profit Loss
ProfitLoss
-42021727
us-gaap Share Based Compensation
ShareBasedCompensation
5467684
us-gaap Share Based Compensation
ShareBasedCompensation
6123554
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
248397
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
326672
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
26380
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
0
us-gaap Depreciation
Depreciation
192064
us-gaap Depreciation
Depreciation
202909
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1191940
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
202304
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
287224
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
86294
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1260585
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
4506394
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-45406010
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-30978208
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
16317
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7806
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
92938213
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
0
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
36000000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-56954530
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-7806
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
189811611
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1123427
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4623251
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
96665
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
61529
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1220092
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
194496391
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-101140448
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
163510377
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
229790989
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
77858311
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
128650541
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
241368688
us-gaap Interest Paid Net
InterestPaidNet
981833
us-gaap Interest Paid Net
InterestPaidNet
1011000
us-gaap Nature Of Operations
NatureOfOperations
<p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1. NATURE OF BUSINESS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aldeyra Therapeutics, Inc., together with its wholly-owned subsidiaries (the “Company” or “Aldeyra”), a Delaware corporation, is a clinical-stage biotechnology company developing innovative therapies designed to treat immune-mediated diseases.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company’s principal activities to date include research and development activities along with related general business planning, including raising capital.</span></p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions, including fair value estimates for investments that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of expenses during the reporting periods. The Company’s management evaluates its estimates and assumptions on an ongoing basis. Management’s most significant estimates in the Company’s condensed consolidated financial statements include, but are not limited to, clinical trial accruals, deferred and accrued research and development costs, stock-based compensation, and accounting for income taxes and related valuation allowance. Although these estimates and assumptions are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</span>
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6588585
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6588585
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5110798
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5110798
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
128650541
CY2022Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
56678860
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
229790989
CY2021Q4 us-gaap Marketable Securities
MarketableSecurities
0
CY2022Q3 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
0
CY2021Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
0
CY2022Q3 us-gaap Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
2935174
CY2021Q4 us-gaap Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
2404145
CY2022Q3 us-gaap Prepaid Insurance
PrepaidInsurance
764700
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
435410
CY2022Q3 us-gaap Other Assets Miscellaneous Current
OtherAssetsMiscellaneousCurrent
453847
CY2021Q4 us-gaap Other Assets Miscellaneous Current
OtherAssetsMiscellaneousCurrent
122226
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4153721
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2961781
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2234358
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1512885
CY2022Q3 aldx Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
7339568
CY2021Q4 aldx Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
8415560
CY2022Q3 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
680525
CY2021Q4 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
594908
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10254451
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10523353
CY2022Q3 us-gaap Long Term Loans Payable
LongTermLoansPayable
15000000
CY2021Q4 us-gaap Long Term Loans Payable
LongTermLoansPayable
15000000
CY2022Q3 aldx End Of Term Charge
EndOfTermCharge
859663
CY2021Q4 aldx End Of Term Charge
EndOfTermCharge
703269
CY2022Q3 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
107563
CY2021Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
199566
CY2022Q3 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
12449058
CY2021Q4 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
0
CY2022Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
3303042
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
15503703
CY2021Q4 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
0
CY2021Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
16042500
CY2021Q4 us-gaap Long Term Debt
LongTermDebt
16042500
aldx Deferred Tax Assets Valuation Allowance Percentage
DeferredTaxAssetsValuationAllowancePercentage
1
CY2019 aldx Share Based Compensation Arrangement By Share Based Payment Award Granted Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedPeriod1
P4Y
CY2020 aldx Share Based Compensation Arrangement By Share Based Payment Award Granted Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedPeriod1
P4Y
CY2022 aldx Share Based Compensation Arrangement By Share Based Payment Award Granted Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedPeriod1
P4Y
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
900000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2236771
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1418336
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5467684
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6123554
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4622870
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.73
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1756297
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.05
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
236962
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
4.74
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
738223
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
7.09
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5403982
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.90
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y9M21D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
4897609
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3345947
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
6.11
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y5M4D
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
2720984
CY2022Q3 us-gaap Share Price
SharePrice
5.34
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
191695
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
7096
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
184599
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
184599
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
200000
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.091
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y9M
us-gaap Operating Lease Expense
OperatingLeaseExpense
189000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
184599
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
191695
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
63119
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
128576
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
0
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
0

Files In Submission

Name View Source Status
aldx-20220930_lab.xml Edgar Link unprocessable
0000950170-22-024434-index-headers.html Edgar Link pending
0000950170-22-024434-index.html Edgar Link pending
0000950170-22-024434.txt Edgar Link pending
0000950170-22-024434-xbrl.zip Edgar Link pending
aldx-20220930.htm Edgar Link pending
aldx-20220930.xsd Edgar Link pending
aldx-ex31_1.htm Edgar Link pending
aldx-ex31_2.htm Edgar Link pending
aldx-ex32_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
aldx-20220930_cal.xml Edgar Link unprocessable
aldx-20220930_def.xml Edgar Link unprocessable
aldx-20220930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
aldx-20220930_htm.xml Edgar Link completed
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending